Climb Bio, Inc. (CLYM)

Climb Bio Statistics

Total Valuation

Climb Bio has a market cap or net worth of $541.22 million. The enterprise value is $395.39 million.

Market Cap	541.22M
Enterprise Value	395.39M

Important Dates

The last earnings date was Thursday, May 7, 2026, before market open.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

Climb Bio has 47.77 million shares outstanding. The number of shares has increased by 15.07% in one year.

Current Share Class	47.77M
Shares Outstanding	47.77M
Shares Change (YoY)	+15.07%
Shares Change (QoQ)	+1.24%
Owned by Insiders (%)	1.10%
Owned by Institutions (%)	35.33%
Float	28.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.65
P/TBV Ratio	3.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 27.86, with a Debt / Equity ratio of 0.00.

Current Ratio	27.86
Quick Ratio	26.91
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -30.92% and return on invested capital (ROIC) is -21.93%.

Return on Equity (ROE)	-30.92%
Return on Assets (ROA)	-21.27%
Return on Invested Capital (ROIC)	-21.93%
Return on Capital Employed (ROCE)	-40.51%
Weighted Average Cost of Capital (WACC)	4.42%
Revenue Per Employee	n/a
Profits Per Employee	-$1.82M
Employee Count	29
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +792.13% in the last 52 weeks. The beta is 0.03, so Climb Bio's price volatility has been lower than the market average.

Beta (5Y)	0.03
52-Week Price Change	+792.13%
50-Day Moving Average	8.41
200-Day Moving Average	4.42
Relative Strength Index (RSI)	66.95
Average Volume (20 Days)	983,814

Short Selling Information

The latest short interest is 1.78 million, so 3.72% of the outstanding shares have been sold short.

Short Interest	1.78M
Short Previous Month	1.61M
Short % of Shares Out	3.72%
Short % of Float	6.33%
Short Ratio (days to cover)	3.29

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-60.08M
Pretax Income	-52.79M
Net Income	-52.79M
EBITDA	n/a
EBIT	-60.08M
Earnings Per Share (EPS)	-$0.79

Balance Sheet

The company has $109.56 million in cash and $479,000 in debt, with a net cash position of $145.83 million or $3.05 per share.

Cash & Cash Equivalents	109.56M
Total Debt	479,000
Net Cash	145.83M
Net Cash Per Share	$3.05
Equity (Book Value)	148.09M
Book Value Per Share	3.10
Working Capital	109.33M

Cash Flow

In the last 12 months, operating cash flow was -$53.30 million and capital expenditures -$186,000, giving a free cash flow of -$53.49 million.

Operating Cash Flow	-53.30M
Capital Expenditures	-186,000
Depreciation & Amortization	135,000
Net Borrowing	n/a
Free Cash Flow	-53.49M
FCF Per Share	-$1.12

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Climb Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.07%
Shareholder Yield	-15.07%
Earnings Yield	-9.75%
FCF Yield	-9.88%

Analyst Forecast

The average price target for Climb Bio is $18.83, which is 66.20% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$18.83
Price Target Difference	66.20%
Analyst Consensus	Strong Buy
Analyst Count	13
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1